View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 5, 2016updated 13 Jul 2022 10:15am

Ferring reports Phase III ESTHER trial results of follitropin delta

Swiss-based biopharmaceutical company Ferring Pharmaceuticals has reported a Phase III, evidence-based stimulation trial with a human recombinant follicle-stimulating hormone (FSH) in Europe and Rest of World (ESTHER) trials of follitropin delta for pregnancy-related complexities.

Swiss-based biopharmaceutical company Ferring Pharmaceuticals has reported a Phase III, evidence-based stimulation trial with a human recombinant follicle-stimulating hormone (FSH) in Europe and Rest of World (ESTHER) trials of follitropin delta for pregnancy-related complexities.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Follitropin delta is a recombinant FSH derived from a human cell line (human rFSH).

ESTHER-1 is a randomised, assessor-blind, controlled, multicentre trial, which involved women aged between 18 to 40 undergoing their first cycle of in-vitro fertilisation (IVF) or intracytoplasmic injection (ICSI).

Ferring clinical research and development vice-president Joan-Carles Arce said: "This trial is an integral part of Ferring’s commitment to help couples conceive by translating the practice of personalised medicine into reproductive health and fertility.

"This trial is an integral part of Ferring’s commitment to help couples conceive by translating the practice of personalised medicine into reproductive health and fertility."

"We believe that by focusing on innovative and personalised approaches to treatment, we can continue to lead the way in assisted reproductive technology."

Patients were administered with an individualised dosing regimen of follitropin delta compared to follitropin alfa (conventional dosing regimen).

The individualised dosing regimen for follitropin delta was determined on the basis of the patient’s serum anti-Müllerian hormone (AMH) level and body weight.

This regimen was applied from the first day of controlled ovarian stimulation to determine an appropriate dose of FSH while ensuring minimum risk of poor and excessive ovarian response in IVF or ICSI.

Non-inferiority was exhibited as a part of the co-primary endpoints of ongoing pregnancy rate and ongoing implantation rate for follitropin delta compared to follitropin alfa.

As for secondary endpoints, number of oocytes retrieved and number of blastocysts obtained, were comparable between both groups.

Additionally it displayed a less frequent occurrence of ovarian hyperstimulation syndrome (OHSS) and / or OHSS preventive interventions.

Data from the ESTHER-2 trial, under which a subset of women underwent additional assessor-blind stimulation cycles, showed no increased immunogenicity risk following controlled ovarian stimulation with follitropin delta after exposure in repeated cycles.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena